HIGHLIGHTS
Parenteral diuretics form the cornerstone of treatment of fluid overload in heart failure. The alkaline pH of furosemide USP precludes SC administration.
A novel buffered formulation of furosemide (pH 7.4) was developed for SC infusion using a wearable patch pump. A novel strategy using SC administration of buffered furosemide is introduced for outpatient use, including selfadministration at home. This may help to reduce the patient and economic burden of heart failure.
Sica et al.
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SUMMARY
Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer "hospital-strength" diuresis for outpatient use, including self-administration at home. Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99. There is a large gap between chronic oral diuretic therapy given at home versus IV diuretics adminis- or 80 mg (8 mg/ml in 10 ml) of a novel furosemide buffered solution administered SC with an external infusion pump using a biphasic pattern (30 mg over the first 60 min followed by 12.5 mg/h for 4 h). After a 14-day fluid re-equilibration washout, all subjects received the alternate treatment. Plasma furosemide levels were evaluated over 8 h. Sica et al. For the PK/PD Pivotal study of both the IV and SC administration routes, the following pharmacokinetic Values are mean AE SD, %, or median (interquartile range). *17 patients were enrolled, 1 patient withdrew before dosing. One subject was found to have high pre-dose concentrations of furosemide and was not included in the PK, PD, or statistical analysis.
AMI ¼ acute myocardial infarction; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; eGFR ¼ estimated glomerular filtration rate; IV ¼ intravenous; N/A ¼ not available; NYHA ¼ New York Heart Association; PK/PD ¼ Pharmacokinetic and pharmacokinetic; proBNP ¼ pro-B-type natriuretic protein; SC ¼ subcutaneous.
Sica et al. All parameters were calculated using a noncompartmental analysis (Nuventra). In the First-inMan study, the plasma levels were plotted for proof-of-principal evaluation. All subjects achieved therapeutic plasma furosemide levels of over 1,000 ng/ml within 1 h after subcutaneous (SC) administration, which were maintained for at least 5 h. All subjects achieved therapeutic plasma furosemide levels of over 1,000 ng/ml within 1 h after subcutaneous (SC) administration, which were maintained for at least 6 h. The figure is in semi-log scale. IV ¼ intravenous; PK/PD ¼ Pharmacokinetic and Pharmacodynamic.
completing the PK/PD Pivotal study in each treatment group would provide reasonably precise estimates of the systemic exposure of furosemide (AUC and C max ).
All pharmacokinetic analyses of the PK/PD Pivotal study were performed by Nuventra using Phoenix 
RESULTS
In both the First-in-Man and PK/PD Pivotal studies, the SC administration of furosemide was well tolerated with no evidence of any drug-induced skin reactions. In the First-in-Man study, all 10 subjects completed each of the cross-over treatments. The mean age of the subjects was 69.9 AE 8.6 years, 80%
were male, the body mass index was 27.5 AE 4.5 kg/m 2 , and all were New York Heart Association (NYHA) functional class II ( Table 1) . Abbreviations as in Table 2 .
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Following SC administration, all subjects (n ¼ 10)
achieved typically therapeutic plasma furosemide levels within 30 min of the start of administration (mean 916 AE 302 ng/ml, range 617 to 1,548 ng/ml), with levels of around 2,000 ng/ml (mean 2,129 AE 445 ng/ml, range 1,615 to 3,085 ng/ml) at 60 min ( Figure 1 ).
The plasma furosemide levels in the plateau phase (60 to 300 min) were maintained in a narrow range from the Cmax (67% to 93%). Following oral administration, marked intersubject variation was observed, with a 70-fold difference between the highest and lowest furosemide levels at 30 min (mean 1,745 AE 1,227 ng/ml, range 43 to 2,989 ng/ml) and a 10-fold difference at 60 min (mean 2,620 AE 1,346 ng/ml, range 447 to 4,406 ng/ml). Most subjects experienced a peak level at 60 min, and only 10% maintained plasma levels in the plateau phase of a minimum of 1,000 ng/ml compared with 100% following SC administration ( Figure 1 ). Mean bioavailability (oral to SC) was 61% (range 33% to 96%). Fluid intake during the study was ad libitum (range 1,175 to 2,000 ml over the 8-h time interval). Total urine output was 1,550 ml (range 1,353 to 1,866 ml) after oral administration, and 1,833 ml (range 1,623 to 2,726 ml) after SC delivery.
In the PK/PD Pivotal study, a total of 17 subjects were enrolled, but 1 subject that was randomized to receive IV furosemide first was withdrawn by the investigators before the start of drug administration. All remaining subjects (n ¼ 16) completed the cross-over treatments, and complete pharmacokinetics, pharmacodynamic, and safety data were available for all subjects. One subject was found to have an unexplained high concentration of furosemide in a pre-dose sample (927.6 ng/ml, >35% of Cmax). In accordance with Food and Drug Administration guidance, the subject was excluded from the analyses because the pre-dose concentration was >5% of Cmax. Therefore, 15 subjects were included in the pharmacokinetic, pharmacodynamic, and statistical analyses. The mean age of the participants (n ¼ 15)
was 68 AE 9.6 years, 93.3% were male, and 86.7% were in NYHA functional class II. Overall, 100% of subjects had hypertension, 80.0% had various arrhythmias, 70.6% had history of acute myocardial infarction, and 40.0% had diabetes ( Table 1) .
PHARMACOKINETICS. The time course of plasma furosemide concentrations for both the IV and SC administration routes are presented in Figure 2 .
Following IV administration, the mean furosemide concentrations were highest after the first (7,650 AE 2,050 ng/ml) and second (8,340 AE 2,290 ng/ml) IV bolus injections, for a median t max of 125 min (range 5 to 125 min) and a geometric mean C max of 8,270 ng/ml.
The geometric mean AUC last and AUC N estimates were 12,400 and 12,600 h • ng/ml, respectively, the geometric mean of the t ½ estimates was 151.8 min, and therapeutic levels of furosemide of 1,000 ng/ml were maintained for 90 and 240 min after the first and second IV bolus injections, respectively. All subjects receiving IV furosemide had quantifiable concentrations of furosemide up to 16 h post-dose. The summary statistics of noncompartmental pharmacokinetic parameters for the IV furosemide administration are presented in Table 2 .
Following SC administration, therapeutic furosemide concentrations were observed as early as 30 min (600 AE 209 ng/ml) and 1 h (1,470 AE 321 ng/ml) after the initiation of the infusion, and increased steadily to 1,910 AE 570 ng/ml by 5 h (immediately before removal of the SC infusion), for a median t max of approximately 4 h (range 1 to 5.05 h) and a geometric mean C max of 1,990 ng/ml. The geometric mean AUC last and AUC N estimates were 12,400 and 12,500 h • ng/ml, respectively, the geometric mean of the t ½ estimates was 3.04 h, and therapeutic levels of furosemide of 1,000 ng/ml were maintained up to 6 h. Most subjects (75%) receiving SC furosemide had a quantifiable concentration of furosemide up to 24 h post-dose. The summary statistics of noncompartmental pharmacokinetic parameters for the SC furosemide are presented in Table 3 .
The geometric LSM of AUC last and AUC N for subjects receiving SC furosemide was similar to the reference IV furosemide, with ratios of 99.50% and 99.65%, respectively. The absolute bioavailability of furosemide was 99.65% with 90% CIs of 94.79% to 104.75%
for the AUC N , and 99.50% with 90% CIs of 94.77% to 104.46% for the AUC last . The geometric mean absolute bioavailability for SC furosemide was 99.60%.
PHARMACODYNAMICS. In the PK/PD Pivotal study, fluid intake was controlled and restricted to 100 ml of water every hour starting 2 h before dosing. Administration of IV and SC furosemide resulted in similar degrees of diuresis at both the 0-to 8-h interval (2,718 AE 654 ml and 2,663 AE 1,021 ml for the IV and SC routes, respectively) and the 0-to 24-h interval (3,672 AE 740 ml and 3,614 AE 1,045 ml for the IV and SC routes, respectively) ( Figure 3 (11, 12) . Indeed, the average bioavailability after oral administration of furosemide is highly variable and has been reported to range between 49% and 72% (11, (13) (14) (15) , while individual differences range from below 20% to over 90%.
Parenteral furosemide therapy not only reduces hypervolemia, but in many patients, it also restores oral bioavailability, allowing them to transition more readily back to oral maintenance therapy. Sica et al.
